Page last updated: 2024-09-04

vatalanib and 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole

vatalanib has been researched along with 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole in 1 studies

Compound Research Comparison

Studies
(vatalanib)
Trials
(vatalanib)
Recent Studies (post-2010)
(vatalanib)
Studies
(2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole)
Trials
(2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole)
Recent Studies (post-2010) (2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole)
2764298703

Protein Interaction Comparison

ProteinTaxonomyvatalanib (IC50)2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole (IC50)
G2/mitotic-specific cyclin-B2Homo sapiens (human)10
Cyclin-dependent kinase 1Homo sapiens (human)10
G2/mitotic-specific cyclin-B1Homo sapiens (human)10
Glycogen synthase kinase-3 alphaHomo sapiens (human)4.195
Glycogen synthase kinase-3 betaHomo sapiens (human)1.725
G2/mitotic-specific cyclin-B3Homo sapiens (human)10

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1

Other Studies

1 other study(ies) available for vatalanib and 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007